Effect of maternal antibodies on induction and persistence of vaccine-induced immune responses against bovine viral diarrhea virus type II in young calves

John Ellis Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada S7N 5B4.

Search for other papers by John Ellis in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVP, DACVM
,
Keith West Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada S7N 5B4.

Search for other papers by Keith West in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Victor Cortese Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada S7N 5B4.
Pfizer Animal Health Group, 812 Springdale Dr, Exton, PA 19341-2803.

Search for other papers by Victor Cortese in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DABVP
,
Carrie Konoby Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada S7N 5B4.

Search for other papers by Carrie Konoby in
Current site
Google Scholar
PubMed
Close
 BSc
, and
Dan Weigel Pfizer Animal Health Group, 812 Springdale Dr, Exton, PA 19341-2803.

Search for other papers by Dan Weigel in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective—To determine the effect of maternally derived antibodies on induction of protective immune responses against bovine viral diarrhea virus (BVDV) type II in young calves vaccinated with a modified-live bovine viral diarrhea virus (BVDV) type I vaccine.

Design—Blinded controlled challenge study.

Animals—24 neonatal Holstein and Holstein-cross calves that were deprived of maternal colostrum and fed pooled colostrum that contained a high concentration of (n = 6) or no (18) antibodies to BVDV.

Procedure—At 10 to 14 days of age, 6 seropositive and 6 seronegative calves were given a combination vaccine containing modified-live BVDV type I. All calves were kept in isolation for 4.5 months. Six calves of the remaining 12 untreated calves were vaccinated with the same combination vaccine at approximately 4 months of age. Three weeks later, all calves were challenged intranasally with a virulent BVDV type II.

Results—Seronegative unvaccinated calves and seropositive calves that were vaccinated at 2 weeks of age developed severe disease, and 4 calves in each of these groups required euthanasia. Seronegative calves that were vaccinated at 2 weeks or 4 months of age developed only mild or no clinical signs of disease.

Conclusions and Clinical Relevance—Results indicate that a single dose of a modified-live BVDV type-I vaccine given at 10 to 14 days of age can protect susceptible young calves from virulent BVDV type II infection for at least 4 months, but high concentrations of BVDV-specific maternally derived antibodies can block the induction of the response. (J Am Vet Med Assoc 2001;219:351–356)

Abstract

Objective—To determine the effect of maternally derived antibodies on induction of protective immune responses against bovine viral diarrhea virus (BVDV) type II in young calves vaccinated with a modified-live bovine viral diarrhea virus (BVDV) type I vaccine.

Design—Blinded controlled challenge study.

Animals—24 neonatal Holstein and Holstein-cross calves that were deprived of maternal colostrum and fed pooled colostrum that contained a high concentration of (n = 6) or no (18) antibodies to BVDV.

Procedure—At 10 to 14 days of age, 6 seropositive and 6 seronegative calves were given a combination vaccine containing modified-live BVDV type I. All calves were kept in isolation for 4.5 months. Six calves of the remaining 12 untreated calves were vaccinated with the same combination vaccine at approximately 4 months of age. Three weeks later, all calves were challenged intranasally with a virulent BVDV type II.

Results—Seronegative unvaccinated calves and seropositive calves that were vaccinated at 2 weeks of age developed severe disease, and 4 calves in each of these groups required euthanasia. Seronegative calves that were vaccinated at 2 weeks or 4 months of age developed only mild or no clinical signs of disease.

Conclusions and Clinical Relevance—Results indicate that a single dose of a modified-live BVDV type-I vaccine given at 10 to 14 days of age can protect susceptible young calves from virulent BVDV type II infection for at least 4 months, but high concentrations of BVDV-specific maternally derived antibodies can block the induction of the response. (J Am Vet Med Assoc 2001;219:351–356)

All Time Past Year Past 30 Days
Abstract Views 180 0 0
Full Text Views 1006 892 228
PDF Downloads 163 63 6
Advertisement